BellRing Brands heads into the week after its August 4 earnings release with a telling gap: analysts are raising targets while the stock keeps falling.
The most striking dynamic this week is the contrast between Street optimism and actual price action. BRBR closed at $12.75, down 6.7% on the week and 8% over the past month. Yet on the same day as the print, two analysts raised their targets. TD Cowen lifted to $12 from $11 (while staying at Hold), and DA Davidson moved to $15 from $13 (maintaining Buy). JP Morgan had already moved its target to $17 from $13 just before the print. The consensus mean target now runs near $14.71 — roughly 15% above where the stock is trading — suggesting the Street still sees recovery value, even after sharply cutting estimates earlier in the year. (Several targets were slashed from the $20–$34 range in May, so the current cluster of $12–$17 reflects a recalibrated, not optimistic, Street.)
The bull and bear cases are sharply defined. Bulls point to BellRing's positioning in convenient nutrition and protein shakes — a category with durable long-term demand — and an asset-light model that generates strong free cash flow. The company is also cited as a potential acquisition target. Bears counter that the real problem is structural: gross margins are compressing from input cost inflation and an unfavorable mix shift toward promoted volume. FY26 guidance was lowered, and FY27 revenue growth is projected at just 1%. The EV/EBITDA multiple has compressed to 7.7x, down about 1% over 30 days, while the P/E has contracted to 9.4x — a roughly 13-point drop over the same period. That's a valuation already pricing in significant damage, which is why bulls are leaning back in, even cautiously.
Short interest tells a nuanced story. At 12.3% of free float, bears have real skin in the game — but the trend is shifting. Short interest dropped roughly 16% in late July from around 17.5 million shares to the current 14.7 million. That looks like a meaningful cover rather than noise. Borrow is easy and cheap: availability runs at 2,396% — nearly 24 shares available to borrow for every one already lent out — and the cost to borrow is a negligible 0.48%. The ORTEX short score has also eased from 52.6 on July 23 down to 49.5, having stepped off a temporary spike that coincided with the prior elevated short interest level. Shorts are still present but less aggressive than they were a few weeks ago.
Options positioning adds a wrinkle. The put/call ratio is running at 0.22, barely above its 20-day average of 0.22 — but with a z-score of 2.78, this technically represents the most elevated defensive positioning in that narrow range in weeks. In absolute terms, a PCR of 0.22 is still very low (the 52-week high was 1.08), meaning options activity is overwhelmingly call-dominated. The market is not hedging meaningfully into the post-earnings period; if anything, the options flow leans speculative to the upside, which sits oddly against the weak price performance.
On the institutional side, BlackRock added over 3 million shares as of June 30, bringing its stake to 9.7% — the largest reported holder. Millennium Management also built a position of 3.1% as of June 23, adding more than 3 million shares in the period. These are recent moves by active and systematic managers, arriving near multi-year lows in the stock. The most recent insider activity is modest: a director bought 4,000 shares at $9.24 in May — small in dollar terms but directional, given the stock has since recovered to $12.75.
The next scheduled earnings event is November 16. Between now and then, the key question is whether BellRing's mix shift toward promoted volume stabilizes or deepens — because that is what will determine whether the 1% FY27 revenue growth forecast proves a floor or a ceiling.
See the live data behind this article on ORTEX.
Open BRBR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
